Business

The FINANCIAL -- Novartis on January 17 announced that its supplemental Biologics License Application (sBLA) for KymriahTM (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) who are ineligible for or relapse after autologous stem cell transplant (ASCT) has been ...

More Articles ...

More Articles ...

The FINANCIAL -- Bayer announced on December 13 that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with ...

The FINANCIAL -- Bayer AG has reduced its direct interest in Covestro from 24.6 percent to 14.2 percent, selling a total of 21 million shares at a price of EUR 86.25 per ...

The FINANCIAL -- Novo Nordisk on January 8 confirms that it made a proposal on 22 December 2017 to acquire Ablynx for EUR 28.00 per share in cash and one CVR with total potential cash payments over ...

The FINANCIAL -- Takeda Pharmaceutical Company Limited on January 5 announced its intention to acquire TiGenix NV, an advanced biopharmaceutical company developing novel stem cell therapies for ...